Press Releases

Teleflex Announces First Patient Enrollment in MANTA Ultra Study

07/01/2022

Excerpt from the Press Release: Study Intends to Demonstrate that Ultrasound Allows for Precise Deployment and Positive Positioning of the MANTA® Vascular Closure Device WAYNE, Pa., June 22, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical study that is…

Read More

Sonde Health and Michigan State University Collaborate on Research Study to Assess the Impact of COVID-19 on Physical Activity and Mental Health in Africa

07/01/2022

Sonde’s vocal biomarker technology to analyze ongoing mental and physical health challenges of people across four African countries during the COVID-19 pandemic Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Sonde Health, in collaboration with Michigan State University, University of Botswana, University of Ghana, University of Dar es Salaam, and University of Nigeria, Nsukka, has launched a…

Read More

Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097

07/01/2022

Data show that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement inhibition Excerpt from the Press Release: WALTHAM, Mass., June 23, 2022 /PRNewswire/ — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the Company presented new preclinical data…

Read More

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

06/30/2022

Excerpt from the Press Release: HAMILTON, ON and BOSTON, June 23, 2022 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) applications for [225Ac]-FPI-2059 (FPI-2059) and the…

Read More

DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors

06/30/2022

52% of SKs lesions treated for 28 days cleared completely, reaching a PLA score of 0. 100% of SKs lesions treated for 28 days demonstrated at least a one-point drop in their PLA score and patients experienced no application site reactions. SM-020 is the first and only highly selective topical treatment that results in natural…

Read More

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

06/30/2022

In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported results…

Read More

Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

06/29/2022

Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to evaluate response to treatment and treatment efficacy for patients enrolling in Plus Therapeutics’ ReSPECT-LM clinical trial Excerpt from the Press Release: AUSTIN, Texas and SAN…

Read More

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

06/29/2022

Excerpt from the Press Release: LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine…

Read More

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

06/29/2022

-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant dose-dependent effects on key target engagement biomarkers -Additional presentations to detail clinical data from Tern’s extensive pipeline, including TERN-101 and TERN-201 Excerpt from the Press Release: FOSTER CITY, Calif., June 22, 2022 (GLOBE NEWSWIRE) — Terns…

Read More

CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022

06/28/2022

Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival Excerpt from the Press Release: NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced encouraging seladelpar data in patients…

Read More